Edition:
United States

People: Aldeyra Therapeutics Inc (ALDX.A)

ALDX.A on American Stock Exchange

5.67USD
15 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.67
Open
$5.67
Day's High
$5.67
Day's Low
$5.67
Volume
200
Avg. Vol
531
52-wk High
$16.55
52-wk Low
$5.01

Machatha, Stephen 

Dr. Stephen G. Machatha is Senior Vice President - Technical Operations of the company. Machatha joined Aldeyra in 2016 as Vice President of Chemistry Manufacturing and Controls. He has more than 15 years of experience in strategic, technical, and operational leadership of process development, manufacturing, quality assurance, quality control, regulatory affairs, and commercial supply chain strategies. Prior to joining Aldeyra, Dr. Machatha was Director of Chemistry Manufacturing and Controls and Drug Product Development for Synageva Biopharmaceuticals, a biotechnology company acquired for$9.5 billionby Alexion Pharmaceuticals. Dr. Machatha led the Chemistry Manufacturing and Controls teams involved in the development and regulatory filing of KANUMA™ (sebelipase alfa). Prior to his work at Synageva, Dr. Machatha held scientific and product development roles of increasing responsibilities at Cubist Pharmaceuticals (Acquired by Merck & Co.) and CyDex Pharmaceuticals (Acquired by Ligand Pharmaceuticals). Dr. Machatha attended the University of Arizona, where he received a Ph.D. in Pharmaceutical Sciences, an M.A. in Organic Chemistry, and a B.Sc. in Chemistry.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --